Kerry A. Rogers, MD, discusses phase II findings of a trial with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in chronic lymphocytic leukemia.
Original Article: Fixed-Duration Venetoclax Triplet Active in CLL